# A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis

> **NCT03765788** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Giant Cell Arteritis

## Interventions

- **DRUG:** Secukinumab 300 mg, s.c.
- **DRUG:** Prednisolone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03765788
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-30
- **Primary completion:** 2021-06-08
- **Final completion:** 2021-06-08
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03765788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03765788, "A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03765788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*